Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | UGT8 | Q16880 | 12/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844983 | 0.87 | P2RX3 (0.42) | LOXL2UGT8P2RX3P2RX2ABHD6 | |
| SCHEMBL21814142 | 0.87 | LOXL2 (0.39) | LOXL2UGT8P2RX3P2RX2ABHD6 | |
| SCHEMBL21813978 | 0.86 | UGT8 (0.51) | LOXL2UGT8 | |
| SCHEMBL21814007 | 0.75 | UGT8 (0.56) | UGT8 | |
| SCHEMBL21813930 | 0.75 | UGT8 (0.47) | LOXL2UGT8 | |
| SCHEMBL21813856 | 0.74 | UGT8 (0.59) | UGT8 | |
| SCHEMBL21813796 | 0.73 | UGT8 (0.47) | UGT8 | |
| SCHEMBL21814005 | 0.73 | UGT8 (0.52) | UGT8 | |
| SCHEMBL21813710 | 0.73 | UGT8 (0.51) | UGT8 | |
| SCHEMBL21814076 | 0.73 | UGT8 (0.52) | UGT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861000-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | Genzyme Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072504-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | LOXL2 451/4885UGT8 74/4885P2RX3 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.